How Is Boston Scientific's Stock Performance Compared to Other Medical Device Stocks?
Boston Scientific (BSX), a $69.7B medical tech company, has underperformed peers, down 56.1% from its 52-week high and 49.6% YTD. Q2 earnings beat estimates but the company cut its 2026 EPS outlook, citing weaker demand and competition. Analysts maintain a 'Strong Buy' rating with a $61.04 average price target.
How this was made
The 30-second read
Why it matters
The guidance downgrade is likely to trigger a sell‑off, especially as the stock already trails its health‑care equipment ETF.
Market read
Guidance cut for a large‑cap med‑tech firm, with direct price impact and sector‑wide implications.
What to watch
Potential upcoming FDA approvals or new product launches could offset the guidance shortfall.
Background
Boston Scientific reported better‑than‑expected Q2 EPS but lowered its full‑year outlook due to weaker Watchman demand and increased competition in electrophysiology.
Ticker impact
Boston Scientific cut its 2026 adjusted EPS outlook to $3.28‑$3.32, below analyst estimates, after reporting Q2 EPS of $0.86.
Downward pressure over the next weeks, potential 5‑10% decline.
Guidance revisions are a primary catalyst; the cut is sizable for a large‑cap med‑tech and follows a marginal earnings beat.
Market effects
May weigh on broader medical device sector as investors reassess demand outlook.
Primarily U.S. market impact; limited effect on international peers.
Limited to global med‑tech investors tracking U.S. guidance.
Counterpoint
If the EPS beat holds and the guidance cut is overly cautious, the stock could rebound on a short‑cover rally.
Key entities
- companyBoston Scientific Corporation
Medical device manufacturer (ticker BSX).
